Dr. Jessica Paulus explores opportunities and challenges with using RWD in conducting comparative effectiveness research.
Real-world data (RWD) can provide valuable insights into treatment effectiveness and be used to generate evidence for decision making. Understanding which data, when and how to use it, and special considerations when leveraging for regulatory and other stakeholders are all critical to success for RWD comparative effectiveness research (CER). Dr. Jessica Paulus explores opportunities and challenges with using RWD in conducting CER, including; methods to reduce bias, regulatory considerations, and examples of large real-world datasets and use case applications.
Key Topics Include:
- Explore opportunities and challenges in conducting CER using RWD, including methods to reduce bias
- Identify examples of using large real-world datasets to generate comparative effectiveness insights
- Understand regulatory considerations when using RWD for comparative effectiveness
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Presenters
Senior Director
Research/Epidemiology
OM1 Inc.
Jess Paulus, ScD is the Senior Director of Epidemiology at OM1. She received her doctorate in Epidemiology from Harvard T.H. Chan School of Public Health and holds an adjunct appointment at Tufts University School of Medicine. She leads a team of epidemiologists at OM1 to leverage real world data to inform clinical and regulatory decision making.
Production Partner
OM1
With specialization in chronic conditions, OM1 leverages its extensive, specialty clinical networks and an artificial intelligence (AI) platform to offer enriched health care datasets, research analytics, data modeling, decision support, and retrospective and prospective clinical studies.
Additional Content From OM1
Improving Patient Outcomes: AI-Based Phenotyping for Diagnosis, Treatment, and Clinical Trials
Join a panel of OM1’s clinical experts in cardiometabolic disease, immunology, and mental health as they explore how Artificial Intelligence (AI) can find phenotypic patterns and unlock insights hidden in real-world data.
Cutting Edge Conversations: Addressing COVID-19 During Uncertainty
Hayley Crawford, PhD, and Carl Marci, MD, discuss how their specific industries have developed new innovations in response to the COVID-19 pandemic.
Cutting Edge Conversations: Addressing Orphan and Rare Diseases
Joseph Zabinski, PhD, MEM, and Jonathan Kish, PhD, MPH, discuss how research groups are working in the realm of orphan and rare diseases.
Additional Content From HealthEconomics.Com
Minimizing the Impact of Cross-Cultural Differences in COA Translations
ICON's Account Managers in Language Services will highlight the importance of Linguistic Validation and how equivalence should be a key focus during the development of Clinical Outcome Assessment translations.
Partnering with Disease Registries: The Value and Impact for Real-World Evidence Generation
In this webinar, Evidera experts will present guidance on why strong connections with registry groups and stakeholder populations are important for generating relevant real-world evidence to advance treatments.
Medicare Part D: Price Negotiation Panel Discussion
Hear expert panelists bring their perspectives on critical issues around support for Medicare Part D products' fair market prices.
Related Content
Minimizing the Impact of Cross-Cultural Differences in COA Translations
ICON's Account Managers in Language Services will highlight the importance of Linguistic Validation and how equivalence should be a key focus during the development of Clinical Outcome Assessment translations.
Partnering with Disease Registries: The Value and Impact for Real-World Evidence Generation
In this webinar, Evidera experts will present guidance on why strong connections with registry groups and stakeholder populations are important for generating relevant real-world evidence to advance treatments.
What Every Researcher Needs to Know About Using Medicare Data for Real World Evidence
Join three panelists who provide a practical overview of how and why to use data from Medicare for real world studies.